© 2000 American Heart Association, Inc.
Editorials |
Secretory Group II Phospholipase A2
A Newly Recognized Acute-Phase Reactant With a Role in Atherogenesis
From the Wihuri Research Institute, Helsinki, Finland.
Correspondence to Petri T. Kovanen, MD, PhD, Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland. E-mail petri.kovanen{at}wri.fi
Key Words: atherosclerosis • extracellular matrix • phospholipase A2 • proteoglycans
 |
Introduction |
|---|
 Top Introduction References |
|---|
There is compelling evidence that atherosclerosis is an inflammatory disease.1 Increased levels of markers of systemic inflammation, such as the acute-phase reactant C-reactive protein, have been associated with acute coronary events in patients with atherosclerosis.2 The secretory group II phospholipase A2 (sPLA2) recently has been added to the group of acute-phase reactants,3 and its plasma levels are greatly increased in diseases involving systemic inflammation, such as sepsis and rheumatoid arthritis.4 Thus, hepatocytes synthesize and secrete this enzyme in response to inflammatory cytokines such as interleukin-6, tumor necrosis factor-
, and
interleukin-1.3 Plasma levels of
sPLA2 were found to correlate with levels of
C-reactive protein in patients with atherosclerosis,
and the levels of sPLA2 were found to be good
predictors of coronary events.5 Whether
sPLA2 is causally involved in the pathogenesis of
atherosclerosis has been under investigation during
recent years. PLA2s are enzymes that hydrolyze the acyl group at the sn-2 position of phospholipids. This results in the formation of a free fatty acid and a lysophospholipid that can be further metabolized into lipid mediators, including eicosanoids, platelet-activating factors, and lysophosphatidic acid.4 Mammalian PLA2s are present in both cytosolic and secreted forms. The secretory PLA2s consist of the group I enzyme secreted by the pancreas and the group II enzymes secreted by many cell types in a number of tissues. Group II sPLA2 is a 14-kDa enzyme, which contains 7 disulfide bridges that make it very stable. It is highly cationic, which allows electrostatic interaction between the enzyme and glycosaminoglycans. sPLA2 is optimally active at neutral pH and has an absolute requirement for the presence of millimolar concentrations of calcium, which means that it is optimally active under the conditions prevailing in the extracellular fluids.4
When secreted by cells in response to inflammatory stimuli, sPLA2 is thought to augment the inflammatory process by catalyzing the production of lipid mediators.4 sPLA2 is virtually inactive toward intact cell surfaces.6 Intact cell surfaces lack the phospholipids (phosphatidylglycerol, phosphatidylethanolamine, and phosphatidylserine) that are good substrates for sPLA2 and contain sphingomyelin, which inhibits sPLA2. Intact cell surfaces also have a high surface pressure that inhibits the enzyme.4
Evidence is accumulating that circulating sPLA2 is not only a marker of systemic inflammation but can also alter plasma lipoprotein metabolism. Thus, in human apoB transgenic mice, sPLA2 expression was found to decrease the levels of HDL but did not alter the levels of apoB-containing lipoproteins, suggesting that the primary target of the enzyme is HDL.7 Moreover, in vitro experiments have shown that altered forms of human HDL particles generated during the acute-phase response after surgery, which contain serum amyloid A, are preferentially hydrolyzed by this enzyme.8 In vitro experiments have also shown that sPLA2 can hydrolyze phospholipids of LDL particles and generate small, dense LDL particles.9 This finding is of interest because patients with rheumatoid arthritis, who have high levels of circulating sPLA2, have a low HDL concentration and small, dense LDL particles in their plasma.10
Recent studies of sPLA2 in the arterial wall add important novel aspects to the mechanisms by which sPLA2 could contribute to the development and progression of atherosclerotic lesions. Although virtually no sPLA2 has been found in the normal arterial intima, sPLA2 has consistently been found in atherosclerotic plaques, where it is associated with both smooth muscle cells and macrophages.11 12 13 In an elegant series of experiments, Hurt-Camejo and colleagues have studied the association of sPLA2 with the various components of the extracellular matrix. Originally, the group observed that sPLA2 is associated with collagen fibrils in the intima.14 Later, they studied the binding of sPLA2 to collagen-associated proteoglycans in vitro and found that sPLA2 binds to the glycosaminoglycan chains of biglycan.15 In this issue of Circulation Research, the investigation group reports that sPLA2 can bind to both the core protein and the glycosaminoglycan chains of decorin in vitro.16 This result was strengthened by immunohistochemical demonstration of an association between sPLA2 and decorin in the human arterial intima.
The collagen-associated proteoglycans decorin and biglycan have recently attracted interest in the field of atherosclerosis research because lipid droplets in the arterial intima have been shown to accumulate initially on the fibrils extending from collagen fibers.17 We have shown that decorin can link native LDL to collagen,18 and moreover, that lipoprotein lipase can strongly link both native and oxidized LDL to decorin-coated collagen.19 That sPLA2 also binds to decorin is interesting because PLA2 has been shown to induce fusion of glycosaminoglycan-bound LDL particles.20 Thus, it is possible that decorin is a key factor in the initiation of extracellular lipid accumulation because of its ability to attract not only LDL particles but also various enzymes capable of modifying them. In this issue of Circulation Research, Wight and colleagues point to another important function of decorin in the arterial intima.21 They show that local expression of decorin by cell-mediated gene transfer reduces neointima formation in balloon-injured rat carotid arteries by reducing the amount of the extracellular matrix components versican and fibronectin accumulating in the neointima. According to the results of their cell culture experiments, this effect of decorin likely results from the known ability of decorin to inhibit transforming growth factor-ß activity.22
What could be the substrates of sPLA2 in the
arterial wall? Although sPLA2 can
hydrolyze native LDL particles, this hydrolysis proceeds at a very slow
rate (
1/100 000 of the rate of Escherichia coli membrane
hydrolysis).23 However, lipolysis of LDL by
sPLA2 can still be significant in atherosclerotic
lesions because the local concentration of LDL is very high and a
fraction of the particles are modified into forms that render the
particles a better substrate for sPLA2. Indeed,
aging and even minimal oxidative modification of LDL greatly enhance
the ability of sPLA2 to hydrolyze LDL
particles.23 Moreover, a similar effect can also be
expected from other types of modification that perturb the surface
structure of LDL particles such as sphingomyelin hydrolysis by the
arterial secretory sphingomyelinase.24
Modification of LDL in the arterial wall by sPLA2 has a number of potentially atherogenic effects. Thus, PLA2-modified LDL particles have increased affinity to proteoglycans, which can lead to enhanced retention and extracellular accumulation of the particles.9 20 The modified particles are more susceptible to lipid peroxidation,25 generation of bioactive phospholipids,26 and hydrolysis by secretory sphingomyelinase.27 PLA2 modification of LDL has also been suggested to lead to enhanced uptake of the lipolyzed particles by macrophages, with ensuing intracellular lipid accumulation.28 In addition, both lysophosphatidylcholine and free fatty acids, the products of phospholipid hydrolysis, can be carried to arterial cells either by the lipolyzed particles themselves or by albumin and so induce proatherogenic changes in cells of the arterial wall.29
Mice expressing human sPLA2 were recently shown to have enhanced formation of fatty streak lesions.30 Whether this effect is due to sPLA2 in the circulation, spLA2 in the arterial wall, or both is not known. According to current knowledge, sPLA2 could be proatherogenic both in the circulation and arterial wall. Future work is necessary to improve our understanding of how sPLA2 is involved in the pathogenesis of atherosclerosis.
|
Footnotes |
|---|
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
|
TopIntroductionReferences |
|---|
1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126.
2.
Lagrand WK, Visser CA, Hermens WT, Niessen HW,
Verheugt FW, Wolbink GJ, Hack CE. C-reactive protein as a
cardiovascular risk factor: more than an epiphenomenon?
Circulation. 1999;100:96–102.
3.
Crowl RM, Stoller TJ, Conroy RR, Stoner CR. Induction
of phospholipase A2 gene expression in human
hepatoma cells by mediators of the acute phase response. J
Biol Chem. 1991;266:2647–2651.
4. Murakami M, Nakatani Y, Atsumi G, Inoue K, Kudo I. Regulatory functions of phospholipase A2. Crit Rev Immunol. 1997;17:225–283.[Medline] [Order article via Infotrieve]
5.
Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H,
Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H.
Circulating levels of secretory type II phospholipase
A2 predict coronary events in patients
with coronary artery disease. Circulation. 1999;100:1280–1284.
6. Fourcade O, Simon MF, Viode C, Rugani N, Leballe F, Ragab A, Fournie B, Sarda L, Chap H. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell. 1995;80:919–927.[Medline] [Order article via Infotrieve]
7. de Beer FC, de Beer MC, van der Westhuyzen DR, Castellani LW, Lusis AJ, Swanson ME, Grass DS. Secretory non-pancreatic phospholipase A2: influence on lipoprotein metabolism. J Lipid Res. 1997;38:2232–2239.[Abstract]
8.
Pruzanski W, Stefanski E, de Beer FC, de Beer MC,
Vadas P, Ravandi A, Kuksis A. Lipoproteins are substrates for human
secretory group IIA phospholipase A2:
preferential hydrolysis of acute phase HDL. J Lipid Res. 1998;39:2150–2160.
9.
Sartipy P, Camejo G, Svensson L, Hurt-Camejo E.
Phospholipase A2 modification of low density
lipoproteins forms small high density particles with increased affinity
for proteoglycans and glycosaminoglycans.
J Biol Chem. 1999;274:25913–25920.
10. Hurt-Camejo E, Paredes S, Masana L, Camejo G, Sartipy P, Pedreyno J, Wiklund O. Inflammatory and atherogenic lipoprotein markers in patients with rheumatoid arthritis. Circulation. 1999;100(suppl I):I-813. Abstract.
11. Menschikowski M, Kasper M, Lattke P, Schiering A, Schiefer S, Stockinger H, Jaross W. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis. 1995;118:173–181.[Medline] [Order article via Infotrieve]
12.
Hurt-Camejo E, Andersen S, Standal R, Rosengren B,
Sartipy P, Stadberg E, Johansen B. Localization of nonpancreatic
secretory phospholipase A2 in normal and
atherosclerotic arteries: activity of the isolated enzyme on
low-density lipoproteins. Arterioscler Thromb Vasc Biol. 1997;17:300–309.
13.
Schäfer-Elinder L, Dumitrescu A, Larsson P, Hedin
U, Frostegård J, Claesson HE. Expression of phospholipase
A2 isoforms in human normal and atherosclerotic
arterial wall. Arterioscler Thromb Vasc Biol. 1997;17:2257–2263.
14.
Romano M, Romano E, Björkerud S, Hurt-Camejo E.
Ultrastructural localization of secretory type II phospholipase
A2 in atherosclerotic and nonatherosclerotic
regions of human arteries. Arterioscler Thromb Vasc Biol. 1998;18:519–525.
15.
Sartipy P, Bondjers G, Hurt-Camejo E. Phospholipase
A2 type-II binds to extracellular matrix
biglycan: modulation of its activity on LDL by colocalization in
glycosaminoglycan matrixes. Arterioscler
Thromb Vasc Biol. 1998;18:1934–1941.
16.
Sartipy P, Johansen B, Gåsvik K, Hurt-Camejo E.
Molecular basis for the association of group IIA phospholipase
A2 and decorin in human atherosclerotic lesions.
Circ Res. 2000;86:707–714.
17.
Nievelstein PFEM, Fogelman AM, Mottino G, Frank JS.
Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion
of low density lipoprotein: a deep-etch and immunolocalization study of
ultrarapidly frozen tissue. Arterioscler Thromb. 1991;11:1795–1805.
18.
Pentikäinen MO, Öörni K, Lassila R,
Kovanen PT. The proteoglycan decorin links low density lipoproteins
with collagen type I. J Biol Chem. 1997;272:7633–7638.
19.
Pentikäinen MO, Öörni K, Kovanen PT.
Lipoprotein lipase (LPL) strongly links native and oxidized low density
lipoprotein particles to decorin-coated collagen: roles for both
monomeric and dimeric forms of LPL. J Biol Chem. 2000;275:5694–5701.
20.
Hakala JK, Öörni K, Ala-Korpela M, Kovanen
PT. Lipolytic modification of LDL by phospholipase
A2 induces particle aggregation in the absence
and fusion in the presence of heparin. Arterioscler Thromb Vasc
Biol. 1999;19:1276–1283.
21.
Fischer JW, Kinsella MG, Clowes MM, Lara S, Clowes AW,
Wight TN. Local expression of bovine decorin by cell-mediated gene
transfer reduces neointimal formation after balloon injury
in rats. Circ Res. 2000;86:676–683.
22. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-ß by the proteoglycan decorin. Nature. 1990;346:281–284.[Medline] [Order article via Infotrieve]
23. Eckey R, Menschikowski M, Lattke P, Jaross W. Minimal oxidation and storage of low density lipoproteins result in an increased susceptibility to phospholipid hydrolysis by phospholipase A2. Atherosclerosis. 1997;132:165–176.[Medline] [Order article via Infotrieve]
24.
Marathe S, Kuriakose G, Williams KJ, Tabas I.
Sphingomyelinase, an enzyme implicated in atherogenesis, is present
in atherosclerotic lesions and binds to specific components of the
subendothelial extracellular matrix. Arterioscler
Thromb Vasc Biol. 1999;19:2648–2658.
25. Neuzil J, Upston JM, Witting PK, Scott KF, Stocker R. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase–induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins. Biochemistry. 1998;37:9203–9210.[Medline] [Order article via Infotrieve]
26.
Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH,
Huber J, Faull KF, Grass DS, Navab M, Fogelman AM, de Beer FC, Lusis
AJ, Berliner JA. Role of group II secretory phospholipase
A2 in atherosclerosis, II:
potential involvement of biologically active oxidized phospholipids.
Arterioscler Thromb Vasc Biol. 1999;19:1291–1298.
27.
Schissel SL, Jiang X, Tweedie-Hardman J, Jeong T,
Camejo EH, Najib J, Rapp JH, Williams KJ, Tabas I. Secretory
sphingomyelinase, a product of the acid sphingomyelinase gene, can
hydrolyze atherogenic lipoproteins at neutral pH: implications for
atherosclerotic lesion development. J Biol Chem. 1998;273:2738–2746.
28. Aviram M, Maor I. Phospholipase A2-modified LDL is taken up at enhanced rate by macrophages. Biochem Biophys Res Commun. 1992;185:465–472.[Medline] [Order article via Infotrieve]
29. Hurt-Camejo E, Camejo G. Potential involvement of type II phospholipase A2 in atherosclerosis. Atherosclerosis. 1997;132:1–8.[Medline] [Order article via Infotrieve]
30.
Ivandic B, Castellani LW, Wang XP, Qiao JH, Mehrabian
M, Navab M, Fogelman AM, Grass DS, Swanson ME, de Beer MC, de Beer F,
Lusis AJ. Role of group II secretory phospholipase
A2 in atherosclerosis, I:
increased atherogenesis and altered lipoproteins in transgenic mice
expressing group IIa phospholipase A2.
Arterioscler Thromb Vasc Biol. 1999;19:1284–1290.
This article has been cited by other articles:
 |
|
 |
|
  D. Divchev, C. Grothusen, M. Luchtefeld, M. Thoenes, F. Onono, R. Koch, H. Drexler, and B. Schieffer Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease Eur. Heart J., August 2, 2008; 29(16): 1956 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jaulmes, B. Janvier, M. Andreani, and M. Raymondjean Autocrine and Paracrine Transcriptional Regulation of Type IIA Secretory Phospholipase A2 Gene in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1161 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hurt-Camejo, G. Camejo, H. Peilot, K. Oorni, and P. Kovanen Phospholipase A2 in Vascular Disease Circ. Res., August 17, 2001; 89(4): 298 - 304. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||